Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2
- PMID: 8326126
Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2
Abstract
Tumor specific immunity is mediated by CTL that recognize peptide Ag in the context of MHC class I molecules and by Th cells that recognize peptide Ag in the context of MHC class II molecules. To clarify the relative importance of MHC class I and II Ag in tumor rejection, we transfected a K1735 melanoma that did not express constitutively either MHC class I or II Ag with H-2Kk and/or I-Ak genes and determined their tumorigenicity. K1735 transfectants expressing either Kk or Ak Ag alone produced tumors in normal C3H mice, whereas most transfectants that expressed both molecules were rejected in normal C3H mice but produced tumors in nude mice. However, the Ak Ag requirement can be substituted by IL-2 because transfection of Kk-positive/Ak-negative K1735 cells with the IL-2 gene also resulted in abrogation of tumorigenicity in normal C3H mice but not in nude mice. Similarly, transfection of Kk-negative/Ak-positive K1735 cells with IFN-gamma gene resulted in induction of MHC class I Ag as well as rejection of these tumors in normal C3H mice. The rejection of K1735 transfectants expressing Kk and Ak Ag in normal C3H mice required both CD4+ and CD8+ T cells. In addition, the transplantation immunity induced by K1735 transfectants expressing both Kk and Ak Ag completely cross-protected mice against challenge with Kk-positive transfectants but only weakly protected them against challenge with parental K1735 cells or Ak-positive transfectants. These results indicate that expression of either MHC class I or II Ag alone is insufficient to cause the rejection of K1735 melanoma in syngeneic hosts and that both Ag are necessary. In addition, our data suggest that the failure of Kk-positive K1735 cells to induce a primary tumor rejection response in normal C3H mice may result from their inability to induce the helper arm of the antitumor immune response.
Similar articles
-
Rejection of mouse sarcoma cells after transfection of MHC class II genes.J Immunol. 1990 May 15;144(10):4068-71. J Immunol. 1990. PMID: 2332639
-
Fibrosarcoma cells expressing allogeneic MHC Class II antigens induce protective antitumor immunity.J Immunol. 1995 Jan 15;154(2):738-43. J Immunol. 1995. PMID: 7814880
-
Presentation of endogenous tumor antigens to CD4+ T lymphocytes by murine melanoma cells transfected with major histocompatibility complex class II genes.J Leukoc Biol. 1994 Oct;56(4):469-74. doi: 10.1002/jlb.56.4.469. J Leukoc Biol. 1994. PMID: 7930943
-
Bacterial antigen delivery systems: phagocytic processing of bacterial antigens for MHC-I and MHC-II presentation to T cells.Behring Inst Mitt. 1997 Feb;(98):197-211. Behring Inst Mitt. 1997. PMID: 9382741 Review.
-
Influence of major histocompatibility complex class I, class II and TLA genes on tumor rejection.Semin Cancer Biol. 1991 Oct;2(5):311-9. Semin Cancer Biol. 1991. PMID: 1773047 Review.
Cited by
-
Locus-specific de novo methylation down-regulates MHC class I in S49 lymphomas.Immunogenetics. 1996;43(1-2):63-7. doi: 10.1007/BF00186605. Immunogenetics. 1996. PMID: 8537124 No abstract available.
-
Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors.J Exp Med. 1998 Mar 2;187(5):693-702. doi: 10.1084/jem.187.5.693. J Exp Med. 1998. PMID: 9480979 Free PMC article.
-
Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11.J Exp Med. 1999 Mar 1;189(5):871-6. doi: 10.1084/jem.189.5.871. J Exp Med. 1999. PMID: 10049951 Free PMC article.
-
Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy.Cancer Immunol Immunother. 2004 Mar;53(3):166-75. doi: 10.1007/s00262-003-0475-7. Epub 2003 Dec 18. Cancer Immunol Immunother. 2004. PMID: 14685781 Free PMC article. Review.
-
The E75 HER2/neu peptide vaccine.Cancer Immunol Immunother. 2008 Oct;57(10):1511-21. doi: 10.1007/s00262-008-0540-3. Epub 2008 Jun 7. Cancer Immunol Immunother. 2008. PMID: 18536917 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Research Materials